DSP Mutual Fund · #153594
DSP Nifty Healthcare Index Fund - Direct Plan - Growth
Other · Index Funds · Direct · Growth
Direct TER: 0.40% · as of
5-year NAV · change the window using the controls in the rolling-returns card below ↓
2025-06-20 → 2026-10-22
Latest NAV
₹11.0430
as of 2026-10-22 · +0.05% vs 2026-10-21
Earliest NAV in archive
2025-06-20
AMFI archive begins Apr 2006
Trailing CAGR vs assigned benchmark
| Window | Scheme CAGR | Benchmark CAGR | Excess | Period |
|---|---|---|---|---|
| 1y | +3.81% | -12.41%* | +16.22% | 2025-10-23 → today · 1.0y |
Benchmark assignment is mapped by category and sub-category from public sources.
* The total-return version of this benchmark is no longer published,
so starred rows use its price index, which excludes dividends. That understates the benchmark by roughly its
dividend yield (about 1.2% a year) and overstates Excess by the same.
"Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).
Rolling 1-year returns distribution · 85 daily entry points · last 5 years
Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.
Median 1y return
+12.7%
Mean 1y return
+12.6%
Best / worst 1y
+18.3% / +3.6%
Windows positive
100%
Monthly returns · since inception (Jun 2025)
How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.1 | +7.1 | -4.5 | +5.0 | +3.2 | +4.9 | +4.0 | +1.1 | -4.8 | -3.9 | · | · | +6.3 |
| 2025 | · | · | · | · | · | · | +3.0 | -3.6 | -1.5 | +3.9 | +2.3 | -2.6 | +1.3 |
| Avg | -5.1 | +7.1 | -4.5 | +5.0 | +3.2 | +4.9 | +3.5 | -1.2 | -3.1 | +3.9 | +2.3 | -2.6 | · |
All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row.
Portfolio mix · asset class breakdown as of 2026-09-30
Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings
Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).
- Large Cap 47.8%
- Mid Cap 48.4%
- Small Cap 3.8%
Index overlap
· vs · share of this fund's AUM that sits in stocks the index also includes43.9%
5 of 20 holdings are index members
Many holdings outside the benchmark universe
As of 2026-09-30
How to read this: This number shows whether the fund invests in the same stocks as the index. It does not show whether the fund weights those stocks like the index. A low number (say below 60%) means the fund holds a meaningful share in stocks the index doesn't carry at all (typical of sectoral, small-cap-tilted or international funds vs a broad benchmark). A high number (80%+) is normal for any large-cap or flexi-cap fund, because Indian active funds mostly pick from the same large and mid-cap stocks as the Nifty 500. It does not on its own signal a closet index fund; to identify that you'd need per-stock weight comparison, which requires index constituent weights we don't currently ingest.
Top stocks held · 20 holdings as of 2026-09-30 See changes vs previous snapshot →
| Stock | Sector | % of fund |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 17.01% |
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 10.44% |
| Apollo Hospitals Enterprise Limited | Healthcare Services | 7.43% |
| Laurus Labs Limited | Pharmaceuticals & Biotechnology | 6.82% |
| Cipla Limited | Pharmaceuticals & Biotechnology | 6.70% |
| Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 6.65% |
| Torrent Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 6.25% |
| Max Healthcare Institute Limited | Healthcare Services | 6.12% |
| Lupin Limited | Pharmaceuticals & Biotechnology | 4.36% |
| Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | 4.09% |
| Fortis Healthcare Limited | Healthcare Services | 3.55% |
| Glenmark Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 3.11% |
| Alkem Laboratories Limited | Pharmaceuticals & Biotechnology | 2.75% |
| Zydus Lifesciences Limited | Pharmaceuticals & Biotechnology | 2.55% |
| Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 2.51% |
| IPCA Laboratories Limited | Pharmaceuticals & Biotechnology | 2.37% |
| Biocon Limited | Pharmaceuticals & Biotechnology | 2.28% |
| Gland Pharma Limited | Pharmaceuticals & Biotechnology | 2.04% |
| Krishna Institute Of Medical Sciences Limited | Healthcare Services | 1.76% |
| Abbott India Limited | Pharmaceuticals & Biotechnology | 1.25% |
Sector mix
- Healthcare 100.0%
Risk metrics, trailing 3y (251 matched daily returns, 2025-06-23 → 2026-07-02)
Calmar
—
CAGR / |max DD| in window
Risk-free rate assumed 6.0% annualised. Benchmark = Nifty 50 TRI (assigned by category mapping).
Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.